Malaysia A map showing 18 of the active clinical trials sites in Malaysia in 2017. The sites are spread across the entire nation and cover a variety of therapeutic areas – including gastroenterology / hepatology, cardiology and oncology – with a cluster of activity in Kuala Lumpur. In terms of…
Malaysia Malaysia’s multi-ethnic population, disease burden, medical infrastructure and research speed, combined with its population’s proficiency in English, make the Southeast Asian nation a potentially excellent regional clinical trials destination. We have a population of 32 million which represents a third of the world’s genomics Dr Akhmal Yusof, CRM Dr…
Opinion Richard Saynor, Senior Vice President, Classic and Established Products at GSK urges big pharma to weigh in on improving global health and well-being to achieve the United Nations Sustainable Development Goals. On the part of pharmaceutical companies, we have a responsibility to help people gain access to high-quality healthcare and…
South Korea South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022 and pledges to expand healthcare coverage to cover 70 percent of the people’s costs. Korea currently runs on a health…
China China’s stupendous economic resurgence over the past four decades never ceases to awe, but what has captured attention in recent years has been the country’s international awakening. Against a nasty backdrop of intensifying populist nationalism, right-wing radicalism and trade protectionism in many advanced economies, Chinese President Xi Jinping’s surprising 2017…
China Cash has always ruled the start-up world and when it comes to the healthcare and life sciences sphere, the heavy investment required for R&D and the long timelines make it even more so. Luckily, China is now the second-largest VC market in the world, and a recent Preqin report highlighted that USD 65…
China The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing and development must also be attributed to the decades of experience and expertise gained from acting as OEM/ODM to global companies, in line with China’s overall positioning as the world’s factory floor. One of the…
Malaysia Shahnas Oli Mohamed, the managing director of Natural Wellness Holdings Sdn Bhd, expresses the important work that Natural Wellness has done to provide natural healthcare products to Malaysian patients, including a specific halal line to satisfy the community’s needs in that area. She also identifies the opportunities Natural Wellness will…
Turkey Murat Kavrar, country manager at Ekol Turkey, offers readers a look at Ekol’s innovative approach to the logistics sector, emphasizing his company’s R&D capacity and eco-friendly solutions that provide client companies with efficient, cost-saving logistics services. We do logistics differently than our competition in Europe Could you introduce Ekol…
Malaysia David Ho, managing director of Hovid, introduces the success story of his family-owned company, which started at a Chinese herbal tea manufacturer and became one of the biggest local generic manufacturers in Malaysia. He also indicates his future plan to increase the company’s international presence. We are now present…
Spain Baltasar Lobato, managing partner of health and life sciences at EY Spain, highlights the major market trends affecting the public and private healthcare sector as well as the pharmaceutical market. He also gives an overview of the complex nature of the Spanish market, the importance of IT in creating a…
Spain The global rich list is splattered with household names who have built their reputation not only through business acumen but through eye-catching purchases such as Steve Balmer’s record buyout of the LA Clippers basketball team for a whopping USD two billion in 2016 or Roman Abramovich´s spectacular 162.5 metres yacht…
See our Cookie Privacy Policy Here